SAN DIEGO — An endovascular ultrasound-based renal denervation (RDN) approach led to greater reductions in blood pressure than radiofrequency ablation in patients with resistant hypertension, according to the first randomized trial to compare the techniques.

A report published by charity organization Cancer Research U.K. suggests obesity is on track to eclipse smoking as the greatest cause of preventable cancer in British women—something experts say could happen by 2043, the Guardian has reported.

A recent meta-analysis published in Circulation: Cardiovascular Quality and Outcomes suggests the benefit of anticoagulation for pulmonary arterial hypertension (PAH) may depend on the subtype of the condition. Mortality rates improved with anticoagulation for patients with idiopathic PAH but worsened for those with scleroderma-associated PAH.

The U.S. Preventive Services Task Force (USPSTF) suggested clinicians continue to offer intensive, multicomponent behavioral interventions for adults with obesity in an updated recommendation statement published Sept. 18 in JAMA.

About 14 percent of older adults hospitalized for common, non-cardiac conditions were discharged with more intensive blood pressure medication, according to an analysis published in The BMJ. The concerning part: More than half of those patients actually demonstrated good blood pressure (BP) control in an outpatient setting, suggesting overtreatment from hospital physicians.

Extensive exposure to air pollutants like nitrogen dioxide and fine particulate matter could feed the development of type 2 diabetes (T2D), Chinese researchers reported in a meta-analysis published this month in the European Journal of Endocrinology.

The European Medicines Agency (EMA) and the FDA said late last week a second toxin that may cause cancer has been detected in valsartan—a common heart drug that has already been recalled in about two dozen countries due to the presence of N-nitrosodimethylamine (NDMA), a probable human carcinogen.

The American Heart Association has tightened its guidelines for diagnosing resistant hypertension—a condition that affects up to 15 percent of patients treated for high blood pressure—according to a scientific statement published this month.